Table 1.
Baseline characteristics of patients in our cohort
| All (62 patients) | Nivolumab (28 patients) | Docetaxel (34 patients) | p value | |
|---|---|---|---|---|
| Median age | 68 years (45‐82) | 69 years (47‐78) | 68 years (45‐82) | 0.9315 |
| Sex | 0.0004 | |||
| Male | 77% | 89.3% | 67.7% | |
| Female | 23% | 10.7% | 32.3% | |
| Smoking status | 0.3572 | |||
| Former/current smokers | 90% | 93% | 88.2% | |
| Never smokers | 10% | 7% | 11.8% | |
| Histology | ||||
| Squamous | 40% | 60.8% | 23.5% | <0.0002 |
| Adenocarcinoma | 48% | 39.2% | 55.9% | 0.0262 |
| Mixed histology/other | 12% | 0% | 20.6% | <0.0005 |
| Biomolecular status (non‐SqCC only) | ||||
| EGFR‐mutated | 16.2% | 9.1% | 19.2% | 0.0649 |
| EGFR wild‐type | 83.8% | 90.9% | 80.8% | 0.0649 |
| KRAS mutated | 8.1% | 9.1% | 7.7% | 0.9188 |
| Treatment lines | 0.205 | |||
| 2nd line | 69.3% | 64.2% | 73.5% | |
| ≥3 lines | 30.7% | 35.8% | 26.5% |